Table 1 Clinicopathologic characteristics of the study patients.

From: The role of adjuvant endocrine treatment in ER+, PR−, HER2− early breast cancer: a retrospective study of real-world data

Characteristic

ER+/PR+(n = 10843)

ER+/PR-(n = 1193)

p-Value

Age(Mean(range))

53.2(16–95)

56.6(22–87)

0.000

ER+(%, median value)

90

80

0.000

 

n(%)

n(%)

 

Menstrual status

  

0.000

Premenopausal

5079(47.1)

320(26.9)

 

Postmenopausal

5700(52.9)

869(73.1)

 

Unknown

64

4

 

T

  

0.048

≤ 2 cm

6762(62.4)

709(59.4)

 

> 2 cm

4081(37.6)

484(40.6)

 

N

  

0.000

0

6814(63.1)

801(67.1)

 

1

2790(25.8)

243(20.4)

 

2–3

1202(11.1)

149(12.5)

 

Unknown

37

0

 

HER2

  

0.202

0

3453(31.8)

402(33.7)

 

1+/2+

7390(68.2)

791(66.3)

 

Ki67

  

0.000

≤ 20%+

6840(63.1)

619(51.9)

 

> 20%+

4003(36.9)

574(48.1)

 

AR

  

0.000

Positive

1280(98.5)

122(93.1)

 

Negative

19(1.5)

9(6.9)

 

Unknown

9544

1062

 

Breast surgery

  

0.005

Lumpectomy

3669(34.0)

355(29.9)

 

Mastectomy

7107(66.0)

831(70.1)

 

Unknown

67

7

 

Axillary surgery

  

0.062

SLNB

4859(46.0)

497(43.1)

 

ALND

5705(54.0)

657(56.9)

 

Unknown

279

39

 

RT

  

0.272

Yes

5181(47.8)

550(46.1)

 

No

5662(52.2)

643(53.9)

 

Chemotherapy

  

0.000

Yes

7289(67.2)

966(81.0)

 

No

3554(32.8)

227(19.0)

 

ET

  

0.003

Yes

9272(85.5)

981(82.2)

 

No

1571(14.5)

212(17.8)

 

ET regimen

  

0.000

SERM

3668(40.0)

264(27.0)

 

SERM + OFS

269(2.9)

16(1.6)

 

AI

4562(49.7)

668(68.2)

 

AI + OFS

678(7.4)

31(3.2)

 

Unknown

95

2

 
  1. HER2, human epidermal growth factor receptor 2; AR, androgen receptor; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; RT, radiation therapy; ET, endocrine treatment; SERM, selective estrogen receptor modulator; OFS, ovarian function suppression; AI, aromatase inhibitor.